EUROAPI Updates Its 2022 Monetary Steerage

  • Non permanent and proactive suspension of prostaglandin manufacturing actions on the Budapest website following a routine inside evaluation

  • Prostaglandin merchandise in the marketplace are inside specification and are appropriate for his or her meant use

  • No affect on the opposite actions of the Budapest website, together with CDMO actions

  • Up to date 2022 steering: EUROAPI now anticipates Internet Gross sales reaching circa € 980 million and a Core EBITDA margin between 12% – 13% in 2022

PARIS, December 07, 2022–(BUSINESS WIRE)–Regulatory Information:

Within the context of a short lived suspension of a few of its manufacturing actions at its Budapest website, EUROAPI (Paris:EAPI) at the moment offers an replace on its monetary steering for 2022.

Throughout an inside evaluation, the Group recognized some Good Manufacturing Practices deficiencies associated to documentation administration. These are related to Manufacturing Information for sure prostaglandin merchandise that are manufactured in a segregated manufacturing unit at its Budapest website. Upon identification, out of an abundance of warning, EUROAPI proactively selected November 30, 2022, to pause batch launch and as a second step to quickly droop prostaglandin manufacturing.

As transparency and high quality are the Group’s highest priorities, we endeavor to maintain our purchasers, companions and the market usually knowledgeable. EUROAPI continues to be finalizing the evaluation and is constructing the motion plan to treatment this case at our Budapest unit. In parallel, the Group has knowledgeable the related well being authorities. EUROAPI doesn’t anticipate any affect on the opposite actions of its Budapest website, together with Contract Improvement and Manufacturing Group (CDMO) actions and, primarily based on the Group’s inside evaluation, considers that the prostaglandin merchandise in the marketplace are inside specification and are appropriate for his or her meant use.

This non permanent and focused pause of manufacturing will have an effect on EUROAPI’s enterprise actions and monetary efficiency. Consequently, primarily based on data out there at the moment, the Group anticipates Internet Gross sales circa € 980 million and a Core EBITDA margin between 12% – 13% in 2022, resulting from lack of gross sales, associated provisions, and remediation prices. The Group estimates that prostaglandin manufacturing might stay suspended for a number of weeks.

EUROAPI’s administration will maintain a convention name at the moment at 8:30 AM CET (Paris time). Please click on right here to affix the reside audio webcast. A replay of the occasion will probably be out there on the Investor Relations webpage.


EUROAPI is targeted on reinventing lively ingredient options to sustainably meet clients’ and sufferers’ wants all over the world. We’re a number one participant in lively pharmaceutical elements with roughly 200 merchandise in our portfolio, providing a big span of applied sciences, whereas creating revolutionary molecules via our Contract Improvement and Manufacturing Group (CDMO) actions.

Taking motion for well being by enabling entry to important therapies conjures up our 3,350 individuals day-after-day. With robust analysis and growth capabilities and 6 manufacturing websites all situated in Europe, EUROAPI ensures API manufacturing of the best high quality to produce clients in additional than 80 international locations. EUROAPI is listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Discover out extra at and comply with us on LinkedIn.

Ahead-Wanting Statements

Sure data contained on this press launch is ahead wanting and never historic knowledge. These forward-looking statements are primarily based on opinions, projections and present assumptions together with, however not restricted to, assumptions regarding the outcomes of the Group’s inside evaluation of the prostaglandin manufacturing course of and ongoing and future assessments and actions doubtlessly taken by regulatory authorities, in addition to the Group’s present and future technique, monetary and non-financial future outcomes and the macroeconomics and enterprise setting by which the Group operates, in addition to occasions, operations, future companies or product growth and potential. Ahead-looking statements are usually recognized by the phrases “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and related expressions. Ahead wanting statements and data don’t represent ensures of future performances, and are topic to identified or unknown dangers, uncertainties and different components, a lot of that are troublesome to foretell and usually outdoors the management of the Group, which might trigger precise outcomes, performances or achievements, or the outcomes of the sector or different occasions, to vary materially from these described or prompt by these forward-looking statements. These dangers and uncertainties embody these which are indicated and detailed in Chapter 3 “Threat components referring to the issuer” of the prospectus permitted by the French Monetary Markets Authority (Autorité des marchés financiers, AMF) on March 31, 2022, underneath quantity 22-076. These forward-looking statements are given solely as of the date of this press launch and the Group expressly declines any obligation or dedication to publish updates or corrections of the forward-looking statements included on this press launch as a way to replicate any change affecting the forecasts or occasions, situations or circumstances on which these forward-looking statements are primarily based.

View supply model on


Media Relations :
Laurence Bollack
Mob.: +33 (0)6 81 86 80 19

Investor Relations :
Guillaume Rosso
Mob.: +33 (0)6 49 51 59 78

Related posts

FACT SHEET: President Biden to Signal Government Order on Making certain Accountable Innovation in Digital Property


Non-public local weather funding is the subsequent finance bubble


Sri Lanka managing with out bridging finance utilizing present inflows: CB Governor